주사 치료 시장 보고서 : 유형별, 약물 종류별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별(2025-2033년)

The global rosacea treatment market size reached USD 2.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.3 Billion by 2033, exhibiting a growth rate (CAGR) of 5.3% during 2025-2033. The rising demand for oral treatments and the expanding pharmaceutical industry are primarily driving the market.

Rosacea treatment refers to preventive measures adopted to cure a chronic skin disease that enlarges blood vessels and causes redness. It includes oral and topical medications, such as antibiotics, alpha agonists, retinoids, corticosteroids, immunosuppressants, and antihypertensive agents. In severe cases, intense pulsed light therapy, laser treatment, and cosmetic surgery are used to remove thickened skin, shrink tissues, and treat rhinophyma. Rosacea treatment assists in easing the symptoms, such as skin inflammation, redness, inflamed eyes, and puss-filled bumps that generally occur on the nose, cheeks, chest, ear, back, and forehead. It also reduces skin discoloration and improves dryness, itching, blurred vision, and sensitivity to light.

Rosacea Treatment Market Trends:

The increasing prevalence of rosacea due to excessive temperature changes, exercise, rising application of cosmetics, pharmaceuticals, and widespread consumption of spicy meals, hot drinks, and alcohol is one of the key factors driving the market growth. Furthermore, increasing demand for oral treatments, such as syrups, tablets, capsules, and liquids, to reduce redness, acne, pimples, and bacterial inflammation, is providing a considerable boost to the market growth. Additionally, the introduction of artificial intelligence (AI)-powered diagnostic tools that utilize digital image shots in natural white light and resolutions to identify facial lesions and symptoms and recognize areas prone to rosacea is creating a positive outlook for the market. Moreover, increasing adoption of combination treatments to reduce initial prominent symptoms, prevent relapse on discontinuation of oral therapy, and maintain long-term control is providing an impetus to the market growth. Other factors, including increasing initiatives and investments by several governments to promote research and development (R&D) activities, rising expenditure capacities of consumers, the launch of new generic products by pharmaceutical companies to increase the efficiency of the treatment, and growing awareness of early diagnosis and effective treatment options, are anticipated to drive market growth.

Key Market Segmentation:

Breakup by Type:

• Erythematotelangiectatic Rosacea
• Papulopustular Rosacea
• Ocular Rosacea
• Phymatous Rosacea

Breakup by Drug Class:

• Antibiotics
• Alpha Agonists
• Retinoids
• Corticosteroids
• Immunosuppressants
• Antihypertensive Agents
• Others

Breakup by Route of Administration:

• Topical
• Oral

Breakup by Distribution Channel:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

Breakup by End User:

• Hospitals
• Homecare
• Specialty Clinics
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Bausch Health Companies Inc., Cellix Bio Private Limited, Colorescience Inc., Croda International Plc, Galderma S.A., LEO Pharma A/S, Lupin Limited, Maruho Co. Ltd., PruGen Pharmaceuticals, Sol-Gel Technologies Ltd. and Timber Pharmaceuticals LLC.

Key Questions Answered in This Report

• 1.What was the size of the global rosacea treatment market in 2024?
• 2.What is the expected growth rate of the global rosacea treatment market during 2025-2033?
• 3.What are the key factors driving the global rosacea treatment market?
• 4.What has been the impact of COVID-19 on the global rosacea treatment market growth?
• 5.What is the breakup of the global rosacea treatment market based on the drug class?
• 6.What is the breakup of the global rosacea treatment market based on the route of administration?
• 7.What are the key regions in the global rosacea treatment market?
• 8.Who are the key players/companies in the global rosacea treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Rosacea Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Erythematotelangiectatic Rosacea
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Papulopustular Rosacea
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Ocular Rosacea
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Phymatous Rosacea
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Drug Class

• 7.1 Antibiotics
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Alpha Agonists
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Retinoids
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Corticosteroids
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Immunosuppressants
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Antihypertensive Agents
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Others
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast

8 Market Breakup by Route of Administration

• 8.1 Topical
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Oral
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

• 9.1 Hospital Pharmacy
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Online Pharmacy
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Retail Pharmacy
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by End User

• 10.1 Hospitals
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Homecare
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Specialty Clinics
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Others
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia-Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Bausch Health Companies Inc.
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
    • 16.3.1.4 SWOT Analysis
  • 16.3.2 Cellix Bio Private Limited
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
  • 16.3.3 Colorescience Inc.
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
  • 16.3.4 Croda International Plc
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 Financials
    • 16.3.4.4 SWOT Analysis
  • 16.3.5 Galderma S.A.
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
  • 16.3.6 LEO Pharma A/S
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
    • 16.3.6.3 SWOT Analysis
  • 16.3.7 Lupin Limited
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 Financials
    • 16.3.7.4 SWOT Analysis
  • 16.3.8 Maruho Co. Ltd.
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
    • 16.3.8.3 SWOT Analysis
  • 16.3.9 PruGen Pharmaceuticals
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
  • 16.3.10 Sol-Gel Technologies Ltd.
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
    • 16.3.10.3 Financials
  • 16.3.11 Timber Pharmaceuticals LLC
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio